corporate profile

Novocure (NASDAQ: NVCR) is a global oncology company striving to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields (TTFields). Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma (GBM) and for the treatment of adult patients with malignant pleural mesothelioma (MPM). In the U.S., our GBM therapy is approved by the U.S. Food and Drug Administration (FDA) under the Premarket Approval (PMA) pathway, and our MPM therapy is approved by the FDA under the Humanitarian Device Exemption (HDE) pathway. We continue to explore the safety and efficacy of TTFields for the treatment of multiple solid tumor cancers of the brain, thorax and abdomen.

corporate presentation clinical evidence
3
FDA-approved indications
27,000+
patients treated through January 2023
$538M
annual net revenues (2022)
$206M
annual R&D investments (2022)
4
pivotal trials in new indications
view all

latest filings

date filing type filing download
May 17, 2023 4/A Amended Statement of Changes in Beneficial Ownership
May 11, 2023 4 Statement of Changes in Beneficial Ownership
May 04, 2023 8-K Current report filing
May 04, 2023 10-Q Quarterly Report
April 26, 2023 8-K Current report filing
April 24, 2023 DEFA14A Additional Proxy Soliciting Materials (definitive)
April 24, 2023 DEF 14A Proxy Statement (definitive)
March 31, 2023 3/A Amended Statement of Beneficial Ownership
March 30, 2023 3 Initial Statement of Beneficial Ownership
March 29, 2023 8-K Current report filing
March 29, 2023 8-K Current report pursuant to Section 13 or 15(d)
March 07, 2023 4 Statement of changes in beneficial ownership of securities
March 07, 2023 4 Statement of changes in beneficial ownership of securities
March 07, 2023 4 Statement of changes in beneficial ownership of securities
March 07, 2023 4 Statement of changes in beneficial ownership of securities
mission, vision and values

mission

Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer by developing and commercializing our innovative therapy.

vision

Patient-forward: aspiring to make a difference in cancer

learn more

contact us

investorinfo@novocure.com
610-723-7427

sign up for email alerts

To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.

"*" indicates required fields

List
This field is for validation purposes and should be left unchanged.